| P2093 | author name string | Yushi Ueki | |
| | Toshitaka Nagao | |
| | Yuichiro Sato | |
| | Yuichiro Tada | |
| | Daisuke Kawakita | |
| | Takafumi Togashi | |
| P2860 | cites work | Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. | Q35587213 |
| | Systemic therapy in the palliative management of advanced salivary gland cancers. | Q36500978 |
| | Trastuzumab for the treatment of salivary duct carcinoma | Q36714388 |
| | Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy | Q36847649 |
| | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 |
| | Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients | Q38428782 |
| | Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature | Q40698680 |
| | Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. | Q54376069 |
| | [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma]. | Q54399082 |
| | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 |
| | Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry | Q73165722 |
| | Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study | Q73783125 |
| | Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland | Q81444823 |
| P433 | issue | 3 | |
| P921 | main subject | trastuzumab | Q412616 |
| | docetaxel | Q420436 |
| | Salivary duct carcinoma | Q7404867 |
| P304 | page(s) | 150-153 | |
| P577 | publication date | 2016-03-22 | |
| P1433 | published in | International Cancer Conference Journal | Q76882255 |
| P1476 | title | Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy | |
| P478 | volume | 5 | |